Canadian HIV Vaccine Initiative program areas

Program areas under the Renewed Canadian HIV Vaccine Initiative are:

  • Advancing Basic Science - activities will be supported to strengthen the capacity of and promote greater involvement and collaboration amongst researchers in Canada and in low-and-middle-income countries who are working in HIV vaccine discovery and social research.
  • Translating Basic Science into Clinical Trials - activities will be supported to assist researchers, in the public and private sectors, in moving promising HIV vaccine candidates from preclinical research into clinical trials in humans.
  • Addressing Enabling Conditions - activities will be supported that involve domestic and international stakeholders in addressing HIV vaccines policy issues, building capacity and promoting global harmonization of regulatory pathways, and improving preparedness.
  • Preventing Mother-to-Child Transmission of HIV - activities will be supported that will improve the efficacy and effectiveness of PMTCT in low-and-middle-income countries, by enhancing the availability, quality and uptake of PMTCT services.
  • Supporting a Coordinated Approach (GoC and Alliance) - activities will provide coordination support and infrastructure to ensure a strong network of HIV vaccine researchers and other vaccine researchers both in Canada and internationally; and ensure effective communications, strategic planning, coordination, reporting and evaluation within the Government of Canada.
Program areas
Key Areas of Focus GoC BMGF Total
HIV Vaccines Advancing Basic Science $27M $7M $34M
Translating Research into Clinical Trials $34M $14M $48M
Addressing Enabling Conditions $13M $7M $20M
Prevention of Mother-to-Child Transmission of HIV $30M $0 $30M
Supporting a Coordinated Approach
(GoC and Alliance)
$7M $0 $7M
Total $111M $28M $139M
Report a problem or mistake on this page
Please select all that apply:

Privacy statement

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: